Rheumatology, Hospital Universitario La Paz, Madrid, Spain.
Instituto de Salud Musculoesquelética, Madrid, Spain.
Ann Rheum Dis. 2022 Mar;81(3):327-334. doi: 10.1136/annrheumdis-2021-221163. Epub 2021 Nov 29.
Non-adherence challenges efficacy and costs of healthcare. Knowledge of the underlying factors is essential to design effective intervention strategies.
To estimate the prevalence of treatment adherence in rheumatoid arthritis (RA) and to evaluate its predictors.
A 6-month prospective cohort study of patients with RA selected by systematic stratified sampling (33% on first disease-modifying rheumatic drug (DMARD), 33% on second-line DMARD and 33% on biologics). The outcome measure was treatment adherence, defined by a score greater than 80% both in the Compliance Questionnaire in Rheumatology and the Reported Adherence to Medication scale, and was estimated with 95% CIs. Predictive factors included sociodemographic, psychological, clinical, drug-related, patient-doctor relationship related and logistic. Their effect on 6-month adherence was examined by multilevel logistic models adjusted for baseline covariates.
180 patients were recruited (77% women, mean age 60.8). The prevalence of adherence was 59.1% (95% CI 48.1% to 71.8%). Patients on biologics showed higher adherence and perceived a higher medication need than the others; patients on second-line DMARDs had experienced more adverse events than the others. The variables explaining adherence in the final multivariate model were the type of treatment prescribed (second-line DMARDs OR=5.22, and biologics OR=3.76), agreement on treatment (OR=4.57), having received information on treatment adaptation (OR=1.42) and the physician perception of patient trust (OR=1.58). These effects were independent of disease activity.
Treatment adherence in RA is far from complete. Psychological, communicational and logistic factors influence treatment adherence in RA to a greater extent than sociodemographic or clinical factors.
不遵守规定会影响医疗效果和成本。了解潜在因素对于设计有效的干预策略至关重要。
评估类风湿关节炎(RA)患者治疗依从性的流行率,并评估其预测因素。
采用系统分层抽样(一线 DMARD 治疗中占 33%、二线 DMARD 治疗中占 33%、生物制剂治疗中占 33%)选择 RA 患者进行为期 6 个月的前瞻性队列研究。治疗依从性的评估采用风湿病依从性问卷和报告药物依从性量表的评分,评分大于 80%,并采用 95%置信区间(CI)进行估计。预测因素包括社会人口统计学、心理、临床、药物相关、医患关系和逻辑相关因素。通过调整基线协变量的多水平逻辑模型来检查这些因素对 6 个月依从性的影响。
共纳入 180 例患者(77%为女性,平均年龄 60.8 岁)。依从性的流行率为 59.1%(95%CI:48.1%至 71.8%)。接受生物制剂治疗的患者比其他患者具有更高的依从性和更高的药物需求,而接受二线 DMARD 治疗的患者比其他患者经历了更多的不良反应。最终多变量模型中解释依从性的变量包括所开治疗药物的类型(二线 DMARDs 的 OR=5.22,生物制剂的 OR=3.76)、对治疗的一致性(OR=4.57)、接受过治疗适应性信息(OR=1.42)和医生对患者信任的感知(OR=1.58)。这些影响独立于疾病活动度。
RA 患者的治疗依从性远未达到完全。心理、沟通和逻辑因素对 RA 治疗依从性的影响大于社会人口统计学或临床因素。